Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis

doi:10.31083/j.rcm.2019.02.31814

Cited by 15 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…dipping status, resistant hypertension, etc.) [ 33 – 35 ]. Luo Y et al’s study demonstrated that 24 h BP profiles were normalized by taking amlodipine at the evening time [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study

2021

View full text Add to dashboard Cite

Background Night-time BP, especially non-dipper, is a stronger predictor of adverse cardiovascular outcomes. Ambulatory blood pressure monitoring (ABPM) is a gold standard for the detection of non-dippers but it often is unavailable and expensive. This study aims to determine clinical risk factors that predict non-dipper. Methods An exploratory traditional case-control study, exclusive sampling of control was conducted from January 2013 to September 2018 to explore clinical risk factors associated with non-dippers in hypertensive patients. Subgroup analysis was performed in each treated and untreated hypertensive patient. The parsimonious predictive score for non-dippers was constructed. Results The study included 208 hypertensive patients receiving 24 h ABPM. There were 104 dippers and 104 non-dippers. Significant clinical risk factors associated with non-dippers were the age of > 65 years, average office diastolic blood pressure (DBP), and fasting plasma glucose of > 5.6 mmol/L. Results of subgroup analysis showed that dyslipidemia, history of coronary artery disease, use of angiotensin-converting enzyme inhibitors (ACEIs) and direct vasodilators, average office DBP, and serum uric acid were associated with non-dippers in treated hypertensive patients, however, there were no risk factors associated with non-dippers in the untreated group. The predictive score for non-dippers in treated group included average office DBP, dyslipidemia, serum uric acid, male, calcium channel blockers and ACEIs use. The area under Receiver Operating Characteristic (AuROC) was 0.723. A cut-off point which was > 0.0701 and prevalence of non-dippers of 46%, this score had a sensitivity of 77.4%, specificity of 65.6%, positive predictive value (PPV) of 66.1%, and negative predictive value (NPV) of 79.6%. For untreated group, age, hemoglobin and body mass index were included in the predictive model. AuROC was 0.74. There was a sensitivity of 51.9%, specificity of 91.2%, PPV of 82.4%, and NPV of 70.5% at the cut-off point of > 0.357, and prevalence of 44%. Conclusion There were several significant clinical risk factors associated with non-dippers in treated hypertensive patients. The predictive score might be useful for the detection of non-dippers; however, it cannot replace ABPM.

show abstract

“…dipping status, resistant hypertension, etc.) [ 33 – 35 ]. Luo Y et al’s study demonstrated that 24 h BP profiles were normalized by taking amlodipine at the evening time [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…[ 33 – 35 ]. Luo Y et al’s study demonstrated that 24 h BP profiles were normalized by taking amlodipine at the evening time [ 35 ]. In contrast with this study, all treated hypertensive patients in our study took CCBs in the morning.…”

Section: Discussionmentioning

confidence: 99%

Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study

2021

View full text Add to dashboard Cite

show abstract

“…The publicly open NIH program announcement (PA-19-034) detailing the classification and identification of 390 understudied druggable genomes was utilized to acquire the list of 261 candidate genes encoding GPCRs and ion channels. The associated literature survey was performed until 9 December 2021, with emphasis on published title words with (1) ion channels since 2017 [4,5,[9][10][11][12][13][14]16,26,27,30,33,[39][40][41][42]44,[46][47][48]53,54,59,61,[69][70][71][72][73][74][75][76][77][78][79][80], (2) ion channel blockers since 2017 [41,[81][82][83][84][85][86][87][88][89][90]…”

Section: Database Literature and Open-access Softwarementioning

confidence: 99%

“…Biomedicines 2022, 10, 594 2 of 21 Amlodipine besylate (brand name, Norvasc; Pfizer), which acts by blocking voltage-gated Ca 2+ channels [28][29][30][31][32], was patented in 1982, and it has since become one of the bestselling anti-hypertensive medications. In 2019, amlodipine was the fifth most prescribed medication in the United States (US) [33].…”

Section: Introductionmentioning

confidence: 99%

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

et al. 2022

View full text Add to dashboard Cite

Mutations of ion channels and G-protein-coupled receptors (GPCRs) are not uncommon and can lead to cardiovascular diseases. Given previously reported multiple factors associated with high mutation rates, we sorted the relative mutability of multiple human genes by (i) proximity to telomeres and/or (ii) high adenine and thymine (A+T) content. We extracted genomic information using the genome data viewer and examined the mutability of 118 ion channel and 143 GPCR genes based on their association with factors (i) and (ii). We then assessed these two factors with 31 genes encoding ion channels or GPCRs that are targeted by the United States Food and Drug Administration (FDA)-approved drugs. Out of the 118 ion channel genes studied, 80 met either factor (i) or (ii), resulting in a 68% match. In contrast, a 78% match was found for the 143 GPCR genes. We also found that the GPCR genes (n = 20) targeted by FDA-approved drugs have a relatively lower mutability than those genes encoding ion channels (n = 11), where targeted genes encoding GPCRs were shorter in length. The result of this study suggests that the use of matching rate analysis on factor-druggable genome is feasible to systematically compare the relative mutability of GPCRs and ion channels. The analysis on chromosomes by two factors identified a unique characteristic of GPCRs, which have a significant relationship between their nucleotide sizes and proximity to telomeres, unlike most genetic loci susceptible to human diseases.

show abstract

“…Impairments in these cells, which ensure proper blood flow and nutrient delivery to all organs, may result in atherosclerotic disease, hypertension, myocardial infarction, or other conditions. 10 Chemicals with KC5 include antihypertensive drugs, 11 arsenic, 12 cadmium, 13 and organophosphate pesticides. 14 …”

mentioning

confidence: 99%

Linking Pollutants and Therapeutics to Heart Health: Key Characteristics of Cardiovascular Toxicants

Schmidt¹

2021

Environ Health Perspect

View full text Add to dashboard Cite

Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis

Cited by 15 publications

References 12 publications

Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study

Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

Linking Pollutants and Therapeutics to Heart Health: Key Characteristics of Cardiovascular Toxicants

Contact Info

Product

Resources

About